Cue Biopharma (CUE) Return on Capital Employed (2018 - 2025)

Cue Biopharma has disclosed Return on Capital Employed across 8 years of filings, most recently posting 23.38% for Q4 2025.

• Return on Capital Employed for Q4 2025 came in at 23.38%, up 1103.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 23.38% (up 1103.0% YoY), and the FY2025 annual result was 23.12%, up 263.0% from the prior year.
• Return on Capital Employed came in at 23.38% for Q4 2025 at Cue Biopharma, up from 25.19% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 23.38% in Q4 2025 to a low of 170.65% in Q3 2024.
• The 5-year median for Return on Capital Employed is 66.86% (2021), against an average of 76.7%.
• Across the five-year window, Return on Capital Employed plunged 7183 bps in 2024 and surged 14545 bps in 2025, its largest moves.
• Cue Biopharma's Return on Capital Employed stood at 63.98% in 2021, then decreased by 15 bps to 73.67% in 2022, then plunged by 47 bps to 108.35% in 2023, then surged by 68 bps to 34.42% in 2024, then soared by 32 bps to 23.38% in 2025.
• The last three Return on Capital Employed figures came in at 23.38% (Q4 2025), 25.19% (Q3 2025), and 52.53% (Q2 2025), per Business Quant data.